Rafael (NYSE:RFL) Trading 4.6% Higher – What’s Next?

Rafael Holdings, Inc. (NYSE:RFL) shares traded up 4.6% on Tuesday . The company traded as high as $3.49 and last traded at $3.3050. Approximately 472,465 shares were traded during mid-day trading, an increase of 50% from the average session volume of 316,004 shares. The stock had previously closed at $3.16.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Rafael from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 28th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Rafael Price Performance

The company has a market capitalization of $171.86 million, a price-to-earnings ratio of -4.86 and a beta of 0.54. The firm has a fifty day simple moving average of $1.73 and a 200 day simple moving average of $1.43.

Rafael (NYSE:RFL) last announced its earnings results on Thursday, June 11th. The company reported ($0.08) earnings per share for the quarter. Rafael had a negative return on equity of 41.27% and a negative net margin of 3,321.74%.The business had revenue of $0.18 million for the quarter.

Institutional Investors Weigh In On Rafael

Several institutional investors and hedge funds have recently added to or reduced their stakes in RFL. Geode Capital Management LLC lifted its holdings in Rafael by 72.9% during the second quarter. Geode Capital Management LLC now owns 451,139 shares of the company’s stock valued at $781,000 after purchasing an additional 190,179 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Rafael during the second quarter worth about $50,000. Cable Car Capital LP purchased a new stake in shares of Rafael during the second quarter worth about $173,000. Vanguard Group Inc. raised its position in shares of Rafael by 10.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,394,726 shares of the company’s stock worth $1,897,000 after purchasing an additional 133,024 shares during the last quarter. Finally, Citadel Advisors LLC raised its position in shares of Rafael by 132.3% during the 3rd quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock worth $99,000 after purchasing an additional 41,335 shares during the last quarter. Hedge funds and other institutional investors own 11.30% of the company’s stock.

About Rafael

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.